Rigel Pharmaceuticals, Inc.
NASDAQ:RIGLBiotechnology
-$0.62 today
- Market cap
- $808.18M
- Beta
- 1.18
- P/E (TTM)
- 1.7
- EPS (TTM)
- $19.78
Volume 0.24M
Average 0.36M
Returns on capital
Rigel Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
93.8%
avg 50.0%
ROIC
28.2%
avg -45.5%
ROA
71.5%
avg -28.1%
Analysis
ROE is currently the strongest return metric at 93.8% versus its period average of 50.0%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Raul R. Rodriguez | President, Chief Executive Officer & Director | USD 1.47M | 65 | 273.36K | 1.48% |
David A. Santos | Executive Vice President & Chief Commercial Officer | USD 865.33K | 63 | 61.62K | 0.33% |
Dean L. Schorno | Executive Vice President & Chief Financial Officer | USD 856.13K | 63 | 8.00K | 0.04% |
Raymond J. Furey | Executive Vice President, Chief Compliance Officer, General Counsel & Corporate Secretary | USD 803.22K | 58 | 50.56K | 0.27% |
Alison L. Hannah | Executive Vice President & Chief Medical Officer | USD 75K | 65 | 35.02K | 0.19% |
Joseph Lasaga | Executive Vice President & Chief Business Officer | — | 51 | 43.75K | 0.24% |
Tarek Sallam | Vice President of Marketing | — | — | — | — |
Julie Patel | Senior Vice President of Human Resources | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 2, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
3
$305,865.00
Net Transaction Value
−$305,865.00
Net selling
Most Active
Ali-Jackson Kamil
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jun 22, 26Jun 22, 2026 | Ali-Jackson Kamil Direct | Sell | $87.5K$87,500.00 |
| May 26, 26May 26, 2026 | Ali-Jackson Kamil Direct | Sell | $72.9K$72,925.00 |
| Feb 20, 26Feb 20, 2026 | MOOS WALTER H Direct | Sell | $145.4K$145,440.00 |
Summary
Insiders reported 0 buys worth $0.00 and 3 sells worth $305,865.00 over the last 12 months. That adds up to net selling of $305,865.00. Ali-Jackson Kamil was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | -21.0% (5yr)1 analysts |
| Revenue | N/A | N/A | +34.8% | +14.3% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | -21.0% (5yr)2 analysts |
| EBIT | N/A | N/A | N/A | +3.7% (5yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +34.8% over three years. Forward estimates point to Revenue at +14.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Rigel Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about RIGL's management, answered from reported figures.
Who manages RIGL?
Rigel Pharmaceuticals, Inc. (RIGL) lists 8 active executives. The top listed executive is Alison L. Hannah, Executive Vice President & Chief Medical Officer.
Are RIGL insiders buying or selling?
Recent insider activity shows net buying of $12.91M.
Continue the stock analysis
Jump to another research area for this company.